FluoGuide A/S

Equities

FLUO

DK0061123312

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Stockholm Other stock markets 10:48:58 2024-04-26 am EDT			5-day change	1st Jan Change
48.9 ^SEK	+7.47%		+9.27%	-20.10%

Mar. 20	FluoGuide A/S Approves Board Changes	CI
Mar. 12	FluoGuide A/S Enters Collaboration Within Robot Assisted Head and Neck Cancer Surgery with Intuitive Surgical, Inc	CI

Fluoguide Q4 2023 - Bright prospects

February 28, 2024 at 08:27 am EST

Redeye comments on Fluoguide’s Q4 2023 report, with the company having recently communicated a strategy update. We believe the company’s new strategy is value-accretive overall, though it likely delays a potential market approval for FG001 by c6-12 months. We do some housekeeping in our model and leave our estimates and valuation largely unchanged.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Latest news about FluoGuide A/S

FluoGuide A/S Approves Board Changes	Mar. 20	CI
FluoGuide A/S Enters Collaboration Within Robot Assisted Head and Neck Cancer Surgery with Intuitive Surgical, Inc	Mar. 12	CI
FluoGuide A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
FluoGuide A/S Provides Strategic Update and Outlines Development Plans Towards Commercialization of FG001	Jan. 08	CI
FluoGuide A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 29	CI
FluoGuide A/S Announces FG001 Meets Primary Endpoint in Phase LLB Trial in Aggressive Brain Cancer	Nov. 13	CI
FluoGuide A/S Confirms Positive Topline Results from Phase IIa Trial of FG001 in Head & Neck Cancer at International Academy of Oral Oncology Conference	Nov. 06	CI
Pfluoguide A/S Provides Positive Interim Data from Phase Lla Trial of Fg001 in Head & Neck Cancer Presented as A Case Report At the World Molecular Imaging Congress in Prague	23-09-07	CI
FluoGuide A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30	CI
Fluoguide A/S Announces Completion of Patient Enrollment and Treatment in the Phase IIb Trial with Fg001 in Patients with Aggressive Brain Cancer	23-08-28	CI
FluoGuide A/S Announces Positive Interim Results from Phase IIa Trial of FG001 in Head & Neck Cancer	23-06-20	CI
Fluoguide A/S Announces Positive Topline Results from Phase Iia Trial of Fg001 in Lung Cancer	23-06-07	CI
FluoGuide A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31	CI
FluoGuide A/S Appoints Michael Thyrring Engsig as Member of the Board of Directors	23-03-21	CI
FluoGuide A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
FluoGuide A/S Updates on Recruitment in Phase IIb Aggressive Brain Cancer Trial with FG001	23-02-27	CI
Sweden's FluoGuide Names Successor as CFO Resigns	23-02-02	MT
FluoGuide A/S Appoints Ole Larsen as Chief Financial Officer	23-02-02	CI
FluoGuide A/S Releases Positive Interim Result of FG001 in Head and Neck Cancer	23-01-09	CI
FluoGuide A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-24	CI
FluoGuide Enrolls First Patient for Technology Platform Study in Head, Neck Cancer	22-11-21	MT
FluoGuide A/S Enrolls First Patient in the Phase IIa Trial in Head and Neck Cancer	22-11-21	CI
FluoGuide A/S Reaches Milestone with FG001 for Phase III Clinical Supply	22-11-08	CI
FluoGuide A/S Releases Positive Interim Result of FG001-CT002	22-11-06	CI
FluoGuide A/S Enrolls the First Patient in the Phase IIb Trial in Aggressive Brain Cancer	22-10-20	CI

Chart FluoGuide A/S

Duration

Period

More charts

Company Profile

FluoGuide A/S is a Denmark-based biotechnology company focused on developing drugs for maximizing surgical outcomes by making cancer fluorescent. The Company is a provider of solutions for maximizing surgical outcome through intelligent targeting. FluoGuide develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The Companyâs main product, FG001, is designed using FluoGuideâs uPAR technology platform to improve surgical precision by illuminating cancer cells intraoperatively. FluoGuide explores FG001 in three other severe cancer indications, namely lung, head & neck, meningioma and low grade glioma.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-29 - Q1 2024 Earnings Release

More about the company

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
FLUOGUIDE A/S	-20.10%	54.4M
THERMO FISHER SCIENTIFIC	+8.07%	219B
DANAHER CORPORATION	+6.59%	183B
INTUITIVE SURGICAL, INC.	+11.26%	133B
BOSTON SCIENTIFIC CORPORATION	+26.57%	108B
EDWARDS LIFESCIENCES CORPORATION	+13.35%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.62%	48.2B
AGILENT TECHNOLOGIES, INC.	-0.93%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+11.54%	39.35B
RESMED, INC.	+26.76%	32.03B

Other Advanced Medical Equipment & Technology

FluoGuide A/S

Equities

FLUO

DK0061123312

Advanced Medical Equipment & Technology

Fluoguide Q4 2023 - Bright prospects

Latest news about FluoGuide A/S

Chart FluoGuide A/S

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Advanced Medical Equipment & Technology